Centene Corp. stock rises toward 52-week high on upgraded 2026 guidance

Published on 09/15/2026 at 23:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Centene Corp. stock approached a new 52-week high around September 14, 2026 as investors reacted to raised full-year 2026 EPS and revenue guidance. The shares have gained strongly year to date while trading below some valuation estimates.

Modernes Gesundheitszentrum-Gebäude mit Patienten am Eingang, Außenaufnahme, Tageslicht — Centene Corp. betreibt moderne ambulante Gesundheitszentren in den USA, ISIN US15133V1035 an der NYSE, Illustration mit AI erstellt.

Centene Corp. stock (ISIN US15133V1035) has moved sharply higher into mid-September, with the shares closing at 69.41 USD on the NYSE on September 14, 2026 after a 4.5 percent gain from the prior session, based on Nasdaq pricing data reported by Yahoo Finance. As TradingView highlighted on September 15, 2026, the latest move comes as the healthcare group sharpened its 2026 guidance and continues to approach a fresh 52-week high.

Guidance for 2026 and improving margins

According to TradingView on September 15, 2026, Centene raised its full-year 2026 adjusted EPS guidance to greater than 4.80 USD per share, reflecting confidence in ongoing operational improvements.

In the same overview, TradingView reports that Centene now guides total revenues for fiscal year 2026 to a range of 193.5 billion to 197.5 billion USD, marking a modest increase versus prior expectations and underpinned by rate increases and membership growth.

The margin picture is also improving: Centene’s health benefits ratio, a key measure of claims costs relative to premiums, fell to 89.6 percent in the second quarter of 2026 from 93.0 percent a year earlier according to TradingView, a 3.4 percentage point improvement that supports the higher earnings outlook.

Stock near 52-week high with strong YTD performance

Centene’s recent price action has pushed the shares close to a new 52-week peak. As Ad-hoc-news reported on September 15, 2026, the stock reached an intraday high of 69.63 USD on September 14, 2026, effectively matching its recent 52-week high level.

The same article from Ad-hoc-news notes that Centene’s stock price has more than doubled from its March 2026 lows near 32 USD, illustrating how the recovery and sector re-rating have played out over recent months.

For a broader performance context, Yahoo Finance wrote on September 15, 2026 that Centene has gained 68.7 percent since the start of 2026, far outpacing the Zacks Medical sector’s 2.4 percent move and the 20 percent return for the Zacks Medical HMOs industry, which underscores how investors are rewarding the company’s guidance and margin progress.

Valuation signals and revenue growth expectations

The rally has lifted Centene’s valuation but some third-party metrics still see room for upside. On September 15, 2026, GuruFocus estimated Centene’s intrinsic GF Value at 78.78 USD per share, implying the stock was approximately 14.5 percent undervalued versus a contemporaneous price of 67.34 USD.

In the same analysis, GuruFocus points out that Centene’s current price-to-sales ratio stands at 0.16, roughly half its historical median of around 0.31 and below the healthcare plans industry median, a discrepancy that reflects both investor caution about future growth and potential valuation support if guidance is delivered.

Looking at forward estimates, Yahoo Finance notes that for the current fiscal year Centene is expected to earn 4.89 USD per share on 196.29 billion USD in revenues, with next fiscal year estimates at 5.34 USD per share on 192.58 billion USD in revenues, suggesting modest topline changes but continued earnings growth.

Risk factors and investor perspective

Despite the improving guidance and margins, some risk factors remain in focus. The analysis from GuruFocus emphasizes that earnings-based valuation metrics such as the price-to-earnings ratio are not meaningful at present due to persistent losses, and that the low price-to-sales ratio partly reflects market skepticism about Centene’s longer-term growth trajectory.

At the same time, Yahoo Finance highlights on September 15, 2026 that Centene’s forward price-to-earnings multiple of 13.58 times for the current year is well below the 22.23 times industry level and the 18.03 times multiple of the S&P 500, alongside an expected revenue growth rate of 0.8 percent and an earnings growth rate of more than 100 percent for the current year.

For investors, the combination of a stock price near its 52-week high, upgraded 2026 guidance, and valuation metrics that still sit below some benchmarks sets up a tension between optimism about execution and caution about regulatory, reimbursement and cost risks that are typical for the managed care and health plans sector.

Centene Corp. stock price as of the last close

As of the last completed trading day before publication, Centene Corp. stock closed at 69.41 USD on the NYSE on September 14, 2026, with that level sitting almost exactly at the recent intraday high of 69.63 USD referenced in multiple market overviews and only a fraction below the 52-week high cited there; trading volume for that session was roughly 4,097,700 shares according to Nasdaq pricing data relayed by Yahoo Finance.